FindTrial
Sign In

Low dose cyclophosphamide

DRUG3 trials

Sponsors

BriaCell Therapeutics Corporation, Centre Hospitalier Universitaire Vaudois

Conditions

Breast CancerBreast Cancer MetastaticBreast NeoplasmMetastatic Breast CancerNon-small Cell Lung CancerOvarian Carcinoma

Phase 1

Combination Study of SV-BR-1-GM With Retifanlimab
CompletedNCT03328026
BriaCell Therapeutics CorporationBreast Cancer, Breast Cancer Metastatic, Breast Neoplasm +1
Start: 2018-03-16End: 2026-03-24Updated: 2026-03-27
Personalized DC Vaccines in Non Small Cell Lung Cancer
Active, not recruitingNCT05195619
Centre Hospitalier Universitaire VaudoisNon-small Cell Lung Cancer
Start: 2022-03-22End: 2027-06-30Target: 16Updated: 2025-07-10
PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma
WithdrawnNCT05714306
Centre Hospitalier Universitaire VaudoisOvarian Carcinoma
Start: 2023-08-01End: 2030-03-31Updated: 2025-03-05

Related Papers

Abstract PS1-13-23: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Clinical Cancer Research2026-02-17
Abstract P5-10-12: Bria-IMT CD8+ Tumor Infiltrating Lymphocytes Turn “Cold” Tumor “Hot” in Metastatic Breast Cancer
Clinical Cancer Research2025-06-13
Abstract P2-10-24: ASTRO-VAC CNS : Bria-IMT in the Management of Tumor Agnostic Metastatic CNS Lesions
Clinical Cancer Research2025-06-13
Abstract PS3-04: Overall Survival Results of Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Clinical Cancer Research2025-06-13
Abstract P1-01-17: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for clinical outcomes in a phase I/II clinical trial using SV-BR-1-GM vaccine with the check point inhibitor retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis
Clinical Cancer Research2025-06-13
Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer.
Journal of Clinical Oncology2025-05-28
Impact of HLA matching on clinical outcomes in a phase 2 trial of Bria-IMT plus anti PD1 in advanced breast cancer.
Journal of Clinical Oncology2025-05-28
Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).
Journal of Clinical Oncology2025-05-28
Abstract CT100: Survival outcomes in a randomized phase 2 of<i>Bria-IMT</i>: An allogeneic whole cell cancer vaccine
Cancer Research2025-04-25
Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.
Journal of Clinical Oncology2024-06-011 citations
SV-BR-1-GM after progression on ADC in patients with metastatic breast cancer.
Journal of Clinical Oncology2024-06-01
Differential efficacy of SV-BR-1-GM in inducing intracranial metastasis regression.
Journal of Clinical Oncology2024-06-01
Abstract PO2-13-06: Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response
Cancer Research2024-05-021 citations
Abstract PO3-05-12: Randomized Phase 2 of Bria-IMT, an Allogenic Human Cell Line with Antigen Presenting Activity, in Heavily Pretreated Metastatic Breast Cancer
Cancer Research2024-05-02
Abstract PO1-20-12: CD8+ Tumor Infiltrating Lymphocytes Turn a Cold Tumor Hot in Metastatic Breast Cancer
Cancer Research2024-05-02
Abstract CT143: Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer
Cancer Research2023-04-14
Abstract P3-07-12: Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell Therapeutic Vaccine in Advanced Metastatic Breast Cancer
Cancer Research2023-03-01
Abstract P1-05-28: Decreases in Circulating Tumor Associated Cells Predicts PFS and OS In A Pooled Analysis Of Phase I Clinical Trials Using SV-BR-1-GM Therapy With Or Without Immune Check-Point Inhibitors In Metastatic Breast Cancer Patients
Cancer Research2023-03-01
Abstract P2-14-02: Overall survival following treatment with a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer
Cancer Research2022-02-15
Abstract CT102: Predictors of response to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I/IIa trials
Cancer Research2021-07-01

6 more papers not shown